Skip to main content

Day: June 1, 2023

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, June 01, 2023 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences:Jefferies Global Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and present on June 8 at 1:00 pm Eastern Daylight Time (EDT) in New York, NY. Citi’s European Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings on June 20-21 in London, UK.All presentations and webcasts will be available on Zymeworks’ website at http://ir.zymeworks.com/events-and-presentations. About Zymeworks Inc. Zymeworks Inc. (Nasdaq: ZYME) is a global biotechnology company committed to the discovery, development,...

Continue reading

IO Biotech Appoints Christine Richter, Ph.D., MBA, as Senior Vice President, Commercial and Program Lead

NEW YORK, June 01, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced today that biopharma executive Christine Richter joined the company as SVP, Commercial and Program Lead for IO102-IO103, the company’s lead cancer vaccine candidate. Dr. Richter will report to IO Biotech’s CEO, Mai-Britt Zocca, Ph.D., and will be a member of the company’s executive team. “Nearing the recruitment of 225 patients in our global Phase 3 clinical trial for IO102-IO103 in patients with advanced metastatic melanoma, we now expect to have a clear line of sight on both the interim analysis next year and a potential U.S. Biologics License Application filing,” said Dr. Zocca. “While we continue our keen focus...

Continue reading

Dyadic to Participate at Upcoming Events in June

JUPITER, Fla., June 01, 2023 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be participating in the following events during the month of June. BIO International Convention, June 5-8, 2023Boston Convention & Exhibition Center, Boston, MAMark Emalfarb, Chief Executive OfficerPresentation: “Transforming Manufacturing & Closing the Technology Gap Between Developed and Developing Countries”Time: Monday, June 5, 2023, 1:30...

Continue reading

Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023

Reaffirms Full Year 2023 Total Revenue Guidance of Between $375 Million and $385 Million Forecasts FIRDAPSE® 2023 Net Product Revenue Guidance of Between $245 Million and $255 Million, an Increase of 17% YoY Forecasts FYCOMPA® 2023 Net Product Revenue of Approximately $130 Million for 11 Months Reaffirms Full Year 2023 Non-GAAP Net Income Forecast of Between $195 Million and $205 Million CORAL GABLES, Fla., June 01, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX) today reported positive momentum for the second quarter of 2023 and reaffirmed its full-year 2023 total revenue guidance of between $375 million and $385 million, representing a 75% to 80% increase in total revenues compared to 2022. The Company also reaffirmed its forecast for the full year 2023 non-GAAP...

Continue reading

Whitestone REIT to Present at Nareit’s REITweek 2023 Investor Conference

HOUSTON, June 01, 2023 (GLOBE NEWSWIRE) — Whitestone REIT (NYSE: WSR) (“Whitestone” or the “Company”) today announced that CEO Dave Holeman, COO Christine Mastandrea and CFO Scott Hogan will participate in a “Fireside Chat” at the Nareit REITweek Investor Conference. The discussion will be moderated by Anthony Hau, Vice President of Equity Research for Truist Securities. When: Wednesday, June 7, 2023, at 1:45 Central / 2:45 EasternLink to Audio: https://ir.whitestonereit.com About Whitestone REIT Whitestone REIT (NYSE: WSR) is a community-centered real estate investment trust (REIT) that acquires, owns, operates, and develops open-air, retail centers located in some of the fastest growing markets in the country: Phoenix, Austin, Dallas-Fort Worth, Houston and San Antonio.  Our centers are convenience focused: merchandised with...

Continue reading

MGP Ingredients Completes Acquisition of Penelope Bourbon

Penelope further strengthens MGP’s portfolio of premium-plus American Whiskey brands; Expected to be immediately accretive to Branded Spirits segment gross margin ATCHISON, Kan., June 01, 2023 (GLOBE NEWSWIRE) — MGP Ingredients, Inc. (Nasdaq: MGPI), a leading provider of distilled spirits, branded spirits, and food ingredient solutions, today announced that its Luxco, Inc. subsidiary has completed its previously announced acquisition of Penelope Bourbon LLC. The completed acquisition welcomes Penelope’s team into the MGP family, bringing innovation capabilities and deep expertise in high-quality whiskeys. It also extends MGP’s portfolio of premium-plus price tier brands and is expected to be immediately accretive to its Branded Spirits segment gross margin and consolidated earnings per share. “The acquisition of Penelope Bourbon...

Continue reading

Magna Completes Acquisition of Veoneer Active Safety Business

Magna Completes Acquisition Magna strengthens global active safety position with acquisitionBroadens Magna’s active safety portfolio Strengthens Magna’s global position as a top active safety supplier Increases scale of sensor, software and systems engineering capabilitiesAURORA, Ontario, June 01, 2023 (GLOBE NEWSWIRE) — Magna strengthens its active safety business with the completion of its acquisition of Veoneer Active Safety from SSW Partners. The deal, which closed today, positions Magna as one of a few suppliers equipped to tackle the increasing complexity coming from advanced software, system and integration challenges by delivering a complete set of offerings to customers. Projected to generate more than $3 billion in sales in 2024, the combined business builds a more comprehensive active safety portfolio across...

Continue reading

Reunion Neuroscience Announces US$13.1 Million Take-Private Transaction with MPM BioImpact

Reunion Common Shareholders to Receive Consideration of US$1.12 Per Share in Cash Represents a 43.1% Premium to the 30-Day Volume Weighted Average Price Reunion Presents Encouraging Phase 1 Final Analysis at American Society of Clinical Psychopharmacology Annual Meeting, Enabling Advancement into Phase 2 in 2H 2023 TORONTO, June 01, 2023 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or the “Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that it has entered into a definitive arrangement agreement dated May 31, 2023 (the “Arrangement Agreement“) with MPM BioImpact (“MPM”), a world-leading biotechnology investment firm, whereby affiliates of MPM...

Continue reading

Reed’s Reports First Quarter 2023 Results

– Strengthened Liquidity Position with Recent $5.6 Million Financing Transactions, Including Strategic Investment – – Reiterates Full Year 2023 Margin and Profitability Targets – NORWALK, Conn., June 01, 2023 (GLOBE NEWSWIRE) — Reed’s, Inc. (OTCQX: REED) (“Reed’s” or the “Company”), owner of the nation’s leading portfolio of handcrafted, natural ginger beverages, is reporting financial results for the three months ended March 31, 2023. Q1 2023 Financial Highlights (vs. Q1 2022):Net sales were $11.2 million compared to $12.2 million. Gross profit was $2.7 million compared to $2.9 million, with gross margin of 24.2% compared to 24.1%. Delivery and handling costs declined 25% to $3.46 per case. Selling, general and administrative expenses declined 27% to $3.2 million. Operating loss improved to $(2.6) million...

Continue reading

MEDIROM Healthcare Technologies Inc. Files Its Annual Report on Form 20-F

NEW YORK, June 01, 2023 (GLOBE NEWSWIRE) — MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (“MEDIROM” or the “Company”), today announced it filed its annual report on Form 20-F for the fiscal year ended December 31, 2022 with the Securities and Exchange Commission (the “SEC”) on May 30, 2023. The annual report on Form 20-F, which contains the Company’s audited consolidated financial statements, can be accessed on the SEC’s website at http://www.sec.gov as well as through the Company’s investor relations website at https://medirom.co.jp/en/ir/. About MEDIROM Healthcare Technologies Inc. MEDIROM, a holistic healthcare company, operates 313 (as of April 30, 2023) relaxation salons across Japan, Re.Ra.Ku®, being its leading brand, and provides healthcare...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.